Clinical trials in GBM failed to demonstrate significant efficacy of FAK inhibition, revealing critical barriers: functional redundancy in signaling networks (e.g., Src kinase, extracellular signal-regulated kinase (ERK)), and - most importantly - the lack of a predictive biomarker identifying true target dependency (32–34). This evidence concerns the gene PTK2 and glioblastoma.